Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSCT MM14 intensified induction, autologous transplantation, consolidation and maintenance in newly diagnosed multiple myeloma
jRCTs071180034Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, cyclophosphamide, dexamethasone, melphalan and lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Complete response rate after consolidation therapy. Started Aug 2015; status: completed.
02
Drugs
bortezomibcyclophosphamidedexamethasonemelphalanlenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs071180034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180034.